Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (434)	5/2/2000 9:59:00 AM
From: juneau_boy	Read Replies (1) \| Respond to of 3559

And another.....what is the timeline and potential of BDNF? TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 2, 2000--Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - news) has received a $3 million milestone payment (less $0.3 million of Japanese withholding tax) from Sumitomo Pharmaceuticals Co., Ltd. related to the development of Regeneron's brain-derived neurotrophic factor (BDNF) in Japan. Regeneron and Sumitomo have been collaborating in the development of BDNF in Japan since 1994. To date, Sumitomo has made a total of $8 million of milestone payments and will make additional payments upon the achievement of specified milestones. Sumitomo will also pay Regeneron a royalty on any sales of BDNF in Japan.